This report
provides comprehensive information on the therapeutic development for
Microscopic Polyangiitis (MPA), complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type, along with latest updates, and
featured news and press releases. It also reviews key players involved in the
therapeutic development for Microscopic Polyangiitis (MPA) and special features
on late-stage and discontinued projects.
Global Markets
Direct's report features investigational drugs from across globe covering over
20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team. Drug profiles/records
featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking,
browser based alert-box and clinical trials registries tracking ensure that the
most recent developments are captured on a real time basis.
Browse
Detail Report With TOC @ http://www.hexareports.com/report/microscopic-polyangiitis-mpa-pipeline-review-h2-2015/details
Scope
-The report provides a snapshot of the global therapeutic landscape of
Microscopic Polyangiitis (MPA)
- The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development
for Microscopic Polyangiitis (MPA) and enlists all their major and minor
projects
- The report summarizes all the dormant and discontinued pipeline
projects
- A review of the Microscopic Polyangiitis (MPA) products under
development by companies and universities/research institutes based on
information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline
projects
- Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of
target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Table Of Content
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Comparative
Analysis 8
Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies
9
Microscopic Polyangiitis (MPA) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Microscopic Polyangiitis (MPA) - Products under Development by Companies
13
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics
Development 14
Aprogen, Inc. 14
ChemoCentryx, Inc. 15
Epirus Biopharmaceuticals, Inc. 16
GlaxoSmithKline Plc 17
Panacea Biotec Limited 18
Sandoz International GmbH 19
Teijin Pharma Limited 20
Microscopic Polyangiitis (MPA) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
Request
A Sample copy of This Report @ http://www.hexareports.com/sample/46612
belimumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-168 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
immune globulin (human) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rituximab biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rituximab biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rituximab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rituximab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 40
Microscopic Polyangiitis (MPA) - Dormant Projects 46
Microscopic Polyangiitis (MPA) - Product Development Milestones 47
Featured News & Press Releases 47
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168,
an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of
Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of
ANCA-Associated Vasculitis 47
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement
C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated
Diseases by the FDA 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
Browse
Full Report @ http://www.hexareports.com/report/microscopic-polyangiitis-mpa-pipeline-review-h2-2015/details
About
Us:
Hexa Reports is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact
Information:
Ryan
Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
No comments:
Post a Comment